Trials with a site in Kansas City, Kansas

Minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), and Membranous nephropathy (MN), generate an enormous individual and societal financial burden, accounting for approximately 12% of prevalent end stage renal disease (ESRD) cases (2005) at an annual cost in the US of more than $3 billion. However, the clinical classification of these diseases is widely believed to be inadequate by the scientific community.

NCT01209000 · Official ClinicalTrials.gov record · University of Michigan

Continuation of the CARRA Registry as described in the protocol will support data collection on patients with pediatric-onset rheumatic diseases. The CARRA Registry will form the basis for future CARRA studies.

NCT02418442 · Official ClinicalTrials.gov record · Duke University

This clinical trial evaluates how well two surgical procedures (bilateral salpingectomy and bilateral salpingo-oophorectomy) work in reducing the risk of ovarian cancer for individuals with BRCA1 mutations. Bilateral salpingectomy involves the surgical removal of fallopian tubes, and bilateral salpingo-oophorectomy involves the surgical removal of both the fallopian tubes and ovaries.

NCT04251052 · Official ClinicalTrials.gov record · NRG Oncology

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

NCT04267848 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)

The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to measure the PK of understudied drugs currently being administered to children per SOC as prescribed by their treating provider.

NCT04278404 · Official ClinicalTrials.gov record · Duke University

NEPTUNE Match is an additional opportunity offered to NEPTUNE study participants to prospectively recruit and communicate patient-specific clinical trial matching with kidney patients and their physician investigators.

NCT04571658 · Official ClinicalTrials.gov record · University of Michigan

This study wants to test the safety and how well it works of BHV-3000 versus dummy treatment (placebo) in the acute treatment of moderate or severe migraine in children and adolescents.

NCT04649242 · Official ClinicalTrials.gov record · Pfizer

This study wants to test the long-term safety of rimegepant in the acute treatment of migraine in children and adolescents (≥ 6 to \< 18 years of age).

NCT04743141 · Official ClinicalTrials.gov record · Pfizer

A prospective, multicenter, single arm, treatment study. The target patient population for this study are adult subjects with WNBAs of the anterior and posterior intracranial circulation.

NCT04839705 · Official ClinicalTrials.gov record · Microvention-Terumo, Inc.

This phase II trial investigates how well the addition of olaparib following completion of surgery and chemotherapy works in treating patients with pancreatic cancer that has been surgically removed (resected) and has a pathogenic mutation in BRCA1, BRCA2, or PALB2. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged.

NCT04858334 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)

A Phase 1 Study Evaluating BAFFR-targeting CAR T Cells for Patients with Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL)

NCT05370430 · Official ClinicalTrials.gov record · PeproMene Bio, Inc.

This phase II trial compares the effect of usual treatment of docetaxel chemotherapy plus trastuzumab, to ado-emtansine (T-DM1) in patients with HER2-positive salivary gland cancer that has come back (recurrent), that has spread from where it first started (primary site) to other places in the body, or cannot be removed by surgery (unresectable). This trial is also testing how well trastuzumab deruxtecan works in treating patients with HER2-low recurrent or metastatic salivary gland cancer.

NCT05408845 · Official ClinicalTrials.gov record · NRG Oncology

This phase II MyeloMATCH treatment trial tests whether the standard approach of cytarabine and daunorubicin in comparison to the following experimental regimens works to shrink cancer in patients with high risk acute myeloid leukemia (AML): 1) daunorubicin and cytarabine liposome alone; 2) cytarabine and daunorubicin with venetoclax; 3) azacitidine and venetoclax; 4) daunorubicin and cytarabine liposome and venetoclax. "High-risk" refers to traits that have been known to make the AML harder to treat.

NCT05554406 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)

This is a Phase 3, multicenter, randomly assigned, neither you nor the study doctors know who gets the real treatment, compared with a dummy treatment study to measure the clinical how well it works, safety, and tolerability of XEN1101 administered as added on top of your current treatment treatment in primary generalized tonic-clonic seizures (PGTCS).

NCT05667142 · Official ClinicalTrials.gov record · Xenon Pharmaceuticals Inc.

This phase II/III trial examines whether patients who have undergone surgical removal of bladder, kidney, ureter or urethra, but require an additional treatment called immunotherapy to help prevent their urinary tract (urothelial) cancer from coming back, can be identified by a blood test. Many types of tumors tend to lose cells or release different types of cellular products including their DNA which is referred to as circulating tumor DNA (ctDNA) into the bloodstream before changes can be seen on scans.

NCT05987241 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)

This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

NCT06058377 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)

This phase I trial tests the safety, best dose, and effectiveness of ZEN003694 in combination with cetuximab and encorafenib in treating patients with colorectal cancer that has not responded to previous treatment (refractory), that has come back after a period of improvement (relapsed), and that has spread from where it first started (primary site) to other places in the body (metastatic). ZEN003694 is a protein inhibitor that binds to BET proteins.

NCT06102902 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)

Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. this study wants to measure the how well it works and safety of TAK-279 versus dummy treatment (placebo) in participants with moderately to severely active Crohn's disease (CD).

NCT06233461 · Official ClinicalTrials.gov record · Takeda

The overall objective of the RESTORATiVE303 study is to measure the safety and the Clostridioides difficile infection (CDI) recurrence rate at Week 8 in participants who receive a 14-day course of VE303 or matching dummy treatment (placebo). The objectives and endpoints are identical for Stage 1 (recurrent CDI) and Stage 2 (high-risk primary CDI).

NCT06237452 · Official ClinicalTrials.gov record · Vedanta Biosciences, Inc.

This study wants to compare the effect of budesonide/albuterol metered-dose inhaler (BDA MDI) with albuterol sulfate metered-dose inhaler (AS MDI), both administered as needed, on the annualized rate of severe asthma exacerbations in adolescents with a documented clinical diagnosis of asthma and at least one severe exacerbation in the prior year.

NCT06307665 · Official ClinicalTrials.gov record · AstraZeneca

This phase III trial compares the effectiveness of rituximab to mosunetuzumab in treating patients with follicular lymphoma with a low tumor burden. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells.

NCT06337318 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)

The study will assess the how well it works and safety of pegozafermin administered in participants with biopsy-confirmed and clinically confirmed compensated cirrhosis due to MASH .

NCT06419374 · Official ClinicalTrials.gov record · Hoffmann-La Roche

The purpose of this protocol is to measure the how well it works and safety of tulisokibart in participants with moderately to severely active Crohn's disease. Study 1's primary hypotheses are that at least 1 tulisokibart dose level is superior to dummy treatment (placebo) in the proportion of participants achieving clinical remission per Crohn's Disease Activity Index score (\<150, US/FDA) or per stool frequency and abdominal pain score (EU/EMA) and in the proportion of participants achieving endoscopic response at Week 52 (US/FDA and EU/EMA), and that at least 1 tulisokibart dose level is superior to dummy treatment (placebo) in the proportion of participants achieving clinical remission per Crohn's Disease Activity Index score (\<150, US/FDA) or per stool frequency and abdominal pain score (EU/EMA) and in the proportion of participants achieving endoscopic response at Week 12 (US/FDA and EU/EMA).

NCT06430801 · Official ClinicalTrials.gov record · Merck Sharp & Dohme LLC

The purpose of TEAM-HF IDE clinical trial is to evaluate safety and effectiveness of the HeartMate 3 LVAS compared to guideline directed medical therapy (GDMT) in a population of ambulatory advanced heart failure patients who are not dependent on intravenous inotrope.

NCT06526195 · Official ClinicalTrials.gov record · Abbott Medical Devices

This phase III trial compares the effect of adding cetuximab to pembrolizumab versus pembrolizumab alone in treating patients with head and neck squamous cell carcinoma (HNSCC) that has come back after a period of improvement (recurrent) and/or that has spread from where it first started (primary site) to other places in the body (metastatic). Cetuximab is in a class of medications called monoclonal antibodies.

NCT06589804 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)

This study wants to measure the ability of dapirolizumab pegol (DZP) as an add-on treatment to standard of care (SOC) medication to achieve clinically relevant long term improvement of moderate to severe disease activity.

NCT06617325 · Official ClinicalTrials.gov record · UCB Biopharma SRL

This study is open to adults who are at least 18 years old living with obesity and have: * a confirmed liver disease called non-alcoholic steatohepatitis (NASH)/metabolic associated steatohepatitis (MASH) and * moderate or advanced liver fibrosis People with a history of acute or chronic liver diseases other than MASH or chronic alcohol intake cannot take part in this study. this study wants to find out whether a medicine called survodutide helps people with MASH and moderate or advanced liver fibrosis improve their liver function.

NCT06632444 · Official ClinicalTrials.gov record · Boehringer Ingelheim

This study will examine the safety and how well it works of TNX-102 SL to reduce ASR symptoms and behavioral changes among patients presenting to the emergency department (ED) after motor vehicle collision (MVC). Specifically, the investigators will perform the Optimizing Acute Stress reaction Interventions with TNX-102 SL (OASIS) Trial, a neither you nor the study doctors know who gets the real treatment compared with a dummy treatment randomly assigned clinical trial (RCT) to determine if TNX-102 SL initiated in the ED in the hours after MVC to high risk individuals, treats/reduces acute stress reaction (ASR)/acute stress disorder (ASD) symptoms (primary outcome), improves neurocognitive function, and prevents/reduces posttraumatic stress (PTS) symptoms (secondary outcomes) long term.

NCT06636786 · Official ClinicalTrials.gov record · University of North Carolina, Chapel Hill

International, Multicenter, neither you nor the study doctors know who gets the real treatment, compared with a dummy treatment and Event-driven study to assess how well it works, whether it is safe and how hard side effects are to live with of Baxdrostat in combination with Dapagliflozin on renal outcomes and cardiovascular mortality in participants with chronic kidney disease and high blood pressure

NCT06742723 · Official ClinicalTrials.gov record · AstraZeneca

This phase II trial compares the use of pembrolizumab and radiation therapy to chemotherapy with cisplatin, gemcitabine, 5-fluorouracil or mitomycin-C and radiation therapy for the treatment of non-muscle invasive bladder cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

NCT06770582 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)

The purpose of this Phase 3b study is to assess the how well it works, whether it is safe and how hard side effects are to live with of remibrutinib after switching from ocrelizumab and compared to continuous ocrelizumab treatment, in patients living with relapsing multiple sclerosis (plwRMS).

NCT06846281 · Official ClinicalTrials.gov record · Novartis Pharmaceuticals

A Multicenter, randomly assigned, neither you nor the study doctors know who gets the real treatment, compared with a dummy treatment, Parallel Group, Phase 3 Study to measure the how well it works and Safety of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT06878261 · Official ClinicalTrials.gov record · AstraZeneca

This is a dose-range finding, neither you nor the study doctors know who gets the real treatment, compared with a dummy treatment, phase IIb study designed to assess how well it works and safety of tozorakimab administered subcutaneously in adult participants with uncontrolled asthma receiving medium-to-high dose inhaled corticosteroids.

NCT06932263 · Official ClinicalTrials.gov record · AstraZeneca

This study is open to adults with chronic heart failure (HF) who have a reduced left ventricular ejection fraction (LVEF) of less than 40%. People can join the study if they have been diagnosed with chronic HF at least 3 months before they start on the study.

NCT06935370 · Official ClinicalTrials.gov record · Boehringer Ingelheim

Study BRT-DA01-301 is a Phase 3 multicenter, randomly assigned, sham surgery-controlled, neither you nor the study doctors know who gets the real treatment study to assess how well it works and safety of bemdaneprocel in approximately 102 adults with Parkinson's Disease (PD).

NCT06944522 · Official ClinicalTrials.gov record · BlueRock Therapeutics

This is a phase 2, randomly assigned, neither you nor the study doctors know who gets the real treatment, 3-arm study for the treatment of Crohn's disease. The primary objective of this study is to assess the how well it works of different doses of SAR442970 compared with dummy treatment (placebo) in participants with moderate to severe Crohn's disease.

NCT06958536 · Official ClinicalTrials.gov record · Sanofi

The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07275315) for the potential treatment of moderate-to-severe asthma. Asthma is a condition that makes it challenging to breathe, which negatively impacts the quality of life and functioning of people who are affected.

NCT06977581 · Official ClinicalTrials.gov record · Pfizer

This study wants to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms or depressive symptoms mixed with anxiety symptoms in participants with Adjustment Disorder due to cancer or other illnesses such as Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), Parkinson's Disease (PD) or Idiopathic Pulmonary Fibrosis (IPF) as compared to active-dummy treatment (placebo).

NCT07002034 · Official ClinicalTrials.gov record · Reunion Neuroscience Inc

LPS18583 is a multinational, randomly assigned, neither you nor the study doctors know who gets the real treatment, compared with a dummy treatment, parallel-group, Phase 4 study with 2 treatment groups. this study wants to assess the effect of dupilumab compared with dummy treatment (placebo) on airway inflammation, resistance, and remodeling including mucus plugging and its association with improvement on lung function, exacerbations, and quality of life improvement in participants aged 40 years of age up to 85 years of age (inclusive).

NCT07053423 · Official ClinicalTrials.gov record · Sanofi

This phase III trial compares the addition of induction chemotherapy, with carboplatin, paclitaxel and pembrolizumab, to chemotherapy and radiation, with cisplatin and pembrolizumab followed by pembrolizumab maintenance for the treatment of patients with cervical cancer that has spread to nearby tissue or lymph nodes (locally advanced). Carboplatin is in a class of medications known as platinum-containing compounds.

NCT07061977 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)

Orelabrutinib is a CNS-penetrable BTK inhibitor. This is a phase 3, randomly assigned, neither you nor the study doctors know who gets the real treatment, parallel-group, multicenter study to measure the how well it works and safety of orelabrutinib compared with dummy treatment (placebo) in patients with PPMS.

NCT07067463 · Official ClinicalTrials.gov record · Zenas BioPharma (USA), LLC

This is a first-in-human, single-arm, open-label study evaluating the safety, tolerability, and preliminary how well it works of ALLO-329 in adults with autoimmune diseases: systemic lupus erythematosus (SLE) with and without renal involvement, idiopathic inflammatory myopathy (IIM), and systemic sclerosis (SSc).The purpose of this trial is to measure the whether it is safe and how hard side effects are to live with of ALLO-329, an allogeneic anti-CD19, anti-CD70 dual chimeric antigen receptor (CAR) T cell therapy, in adults with autoimmune disorders, provide initial evidence of biological activity and clinical response to the treatment and determine the recommended Phase 2 regimen (RP2R).

NCT07085104 · Official ClinicalTrials.gov record · Allogene Therapeutics

This study wants to measure the how well it works, safety, and pharmacokinetics (PK) of prasinezumab compared with dummy treatment (placebo) in participants with early-stage Parkinson's disease (PD) on stable symptomatic this drug alone with levodopa.

NCT07174310 · Official ClinicalTrials.gov record · Hoffmann-La Roche

This study wants to learn how a new medicine called PF-08052667 works when used by itself or together with another medicine called Bacillus Calmette Guerin (BCG), and/or a medicine called sasanlimab. This study is for adults who have a type of bladder cancer that hasn't spread into the muscle layer of the bladder but is more likely to come back or grow.

NCT07206225 · Official ClinicalTrials.gov record · Pfizer

This study wants to measure the long-term safety and effectiveness of the FDA approved VARIPULSE catheter system for pulmonary vein isolation (PVI) in the treatment of participants with symptomatic paroxysmal atrial fibrillation (PAF).

NCT07227532 · Official ClinicalTrials.gov record · Biosense Webster, Inc.

This clinical trial is being done to learn whether using the proactive, graduated dose modification algorithm for leucovorin, 5-fluorouracil (5-FU), and oxaliplatin (FOLFOX) (PAGODA) algorithm to guide chemotherapy dosing for the FOLFOX regimen works to reduce unplanned treatment delays for patients with digestive system cancers compared to usual care. During standard of care treatment, chemotherapy dose changes or treatment delays are typically determined by the treating physician based on factors such as a patient's height, weight, and blood test results obtained before each treatment cycle.

NCT07283939 · Official ClinicalTrials.gov record · Alliance for Clinical Trials in Oncology

Orelabrutinib is a CNS-penetrable BTK inhibitor. This is a phase 3, randomly assigned, neither you nor the study doctors know who gets the real treatment, parallel-group, multicenter study to measure the how well it works and safety of orelabrutinib compared with dummy treatment (placebo) in patients with non-active Secondary Progress MS.

NCT07299019 · Official ClinicalTrials.gov record · Zenas BioPharma (USA), LLC

The objective of this study is to assess the potential for GB-0895 to improve the health of adolescents and adults with severe asthma that is uncontrolled by inhaled corticosteroids (ICS) and conventional asthma controllers. Additional information is available at www.SOLAIRIA.com.

NCT07359846 · Official ClinicalTrials.gov record · Generate Biomedicines

The study is a Phase 3, neither you nor the study doctors know who gets the real treatment, compared with a dummy treatment, randomly assigned withdrawal study to assess the how well it works and safety of AXS-14 in the management of fibromyalgia.

NCT07398417 · Official ClinicalTrials.gov record · Axsome Therapeutics, Inc.

The overarching goal of this program of research is to reduce smoking-related health disparities by increasing smoking cessation among Black adults. The goal of this research proposal is to determine whether more intensive, culturally specific, evidence-based interventions are more effective at promoting long-term cessation and other key patient-centered outcomes compared to the usual evidence-based standard of care: services provided by a state-run quitline.

NCT07419425 · Official ClinicalTrials.gov record · University of Wisconsin, Madison

Background and Rationale Essential tremor (ET) affects over 6 million Americans and approximately 5% of adults over age 60. Patients with ET have a 10-20 times higher risk of developing Parkinson's disease (PD) compared to age-matched populations, with approximately 1% converting to PD annually.

NCT07428447 · Official ClinicalTrials.gov record · CND Life Sciences

The goal of this clinical trial is to evaluate if the study drug will reduce brain and retinal atrophy by reducing inflammation and subsequently slowing neurodegeneration in people with Multiple Sclerosis. The main outcome for the trial is change in normalized brain parenchymal volume (nBPV), measured by magnetic resonance imaging (MRI).

NCT07497399 · Official ClinicalTrials.gov record · Johns Hopkins University

The primary purpose of this study is to measure the how well it works of SL-325 in adult participants with moderate to severely active Crohn's disease. The study consists of a screening period of up to 6 weeks, a 12-week induction period, 38-week maintenance period, 52-week long-term extension period, and a 10-week follow-up period.

NCT07753850 · Official ClinicalTrials.gov record · Shattuck Labs, Inc.